Phase 2 Daro-PET tests short-course darolutamide to boost PSMA PET signal in high-risk localized prostate cancer, guiding improved imaging interpretation.
Jose Mauricio Mota, MD, PhD
Articles by Jose Mauricio Mota, MD, PhD
Latest Updated Articles
Daro-PET: PSMA PET After Short-Course Darolutamide in Prostate CancerFebruary 27th 2026